Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, ...
Read moreSAN DIEGO, Sept. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, ...
Read more© 2022 TheDailyStock.News